Poor
Not Aligned
Patient Risk:
Medium
Summary
Multiple substantial claims are not supported because the provided label excerpts do not cover key areas (indications, administration/dosing details, liver injury/monitoring) and several items are marked “absent from the label” without verified label text. Several safety/monitoring assertions are therefore unreliable relative to the supplied prescribing information.
Category Scores
Accurate Statements
Dantrolene injection works by reducing the release of calcium inside muscle cells.
Supported by 12.1 Mechanism of Action (interfering with release of Ca++ from the sarcoplasmic reticulum; inhibition of calcium release).
By reducing calcium release inside muscle cells, dantrolene injection helps relax skeletal muscle.
Supported by 12.1 Mechanism of Action (dissociates excitation-contraction coupling; reestablishes calcium equilibrium; produces relaxation).
More serious side effects of dantrolene injection can include breathing problems.
Supported by 5 WARNINGS AND PRECAUTIONS (5.1 Muscle Weakness: dyspnea, respiratory muscle weakness, decreased inspiratory capacity) and monitoring for adequate ventilation.
Dantrolene injection may reduce overall strength.
Supported by 5.1 Muscle Weakness (loss of grip strength and weakness in the legs).
Unsupported Statements
Dantrolene injection is used to treat severe muscle spasticity.
Not supported by the supplied label excerpt for Indications and Usage; the excerpt lists malignant hyperthermia (treatment/prevention) rather than muscle spasticity.
Dantrolene injection is used to treat muscle rigidity.
Not supported by the supplied label excerpt for Indications and Usage; the excerpt lists malignant hyperthermia (treatment/prevention) rather than muscle rigidity.
Dantrolene injection is administered by healthcare professionals under medical supervision.
No supporting label text provided in the supplied excerpts.
Dosing of dantrolene injection depends on the patient's condition and response.
No dosing individualized-by-condition/response language is provided in the supplied excerpts.
Clinicians monitor for side effects during dantrolene injection treatment because the drug can affect muscle strength and vital functions.
Partially supported for muscle weakness/ventilation adequacy (5.1) but the broader phrasing about 'vital functions' is not specifically supported by the provided excerpts.
Commonly reported concerns with dantrolene injection include muscle weakness.
The label supports muscle weakness occurrence and counseling (5.1; 17), but 'commonly reported concerns' is a frequency descriptor not explicitly provided in the excerpts.
Commonly reported concerns with dantrolene injection include sedation.
The label supports somnolence/dizziness (5.2; 17), but 'sedation' as a commonly reported concern is not explicitly stated as such in the provided excerpts.
More serious side effects of dantrolene injection can include liver injury.
No liver injury/hepatotoxicity content is present in the supplied label excerpts; therefore this claim is unsupported.
Clinicians monitor patients during dantrolene injection treatment because of the risk of breathing problems and liver injury.
Monitoring for adequate ventilation/breathing adequacy is supported (5.1), but monitoring for liver injury is not supported by the supplied excerpts.
During dantrolene injection treatment, clinicians monitor for worsening weakness.
The label supports not ambulating without assistance until normal strength/balance, but it does not explicitly state 'worsening weakness' monitoring.
During dantrolene injection treatment, clinicians monitor for excessive sedation.
Somnolence/dizziness can occur (5.2), but the label text provided does not explicitly state clinicians monitor for 'excessive sedation.'
During dantrolene injection treatment, clinicians monitor for signs of liver stress.
No liver stress/hepatotoxicity monitoring language is present in the supplied excerpts.
Patients may be monitored for response during dantrolene injection treatment because dantrolene can relax muscles.
No label text provided in the supplied excerpts supporting treatment response monitoring rationale.
Contradictions
Low
AI Statement
Dantrolene injection is used to treat severe muscle spasticity.
Label Reference
1 INDICATIONS AND USAGE (malignant hyperthermia treatment/prevention listed; muscle spasticity not listed in provided excerpt)
Low
AI Statement
Dantrolene injection is used to treat muscle rigidity.
Label Reference
1 INDICATIONS AND USAGE (malignant hyperthermia treatment/prevention listed; muscle rigidity not listed in provided excerpt)
Important Omissions
Boxed warning and contraindications were not evaluated because the relevant label sections were not provided; additionally, claims about liver injury could be materially dependent on missing warning/precaution text.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Unsupported claims include liver injury and liver-stress monitoring, which could misrepresent safety expectations. Some monitoring/admin/dosing statements are also unsupported, while muscle weakness/breathing adequacy concerns are partially supported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Indications are incorrect relative to the provided label excerpt (malignant hyperthermia vs muscle spasticity/rigidity) and liver injury/monitoring claims are unsupported by the supplied label text.
Suggested Improvement
Limit claims to the provided label content: malignant hyperthermia treatment/prevention (Indications and Usage), mechanism of action (12.1), and warnings/monitoring for muscle weakness/ventilation and somnolence/dizziness (5.1, 5.2, 17). Remove unsupported liver injury/stress and avoid frequency/monitoring wording not explicitly stated in the excerpts.